Updated results from mid-stage studies evaluating BeiGene’s (BGNE +0.1%) PD-1 inhibitor tislelizumab continue to demonstrate a treatment effect. The data were presented at the Annual Meeting of the Chinese Society of Clinical Oncology in Xiamen.
https://seekingalpha.com/news/3501121-new-data-beigenes-tislelizumab-continue-show-positive-effect